Long COVID guidelines need to reflect lived experience.
Published in Lancet (London, England)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of ...
...Published in Lancet (London, England)
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3...
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000...
...Published in Lancet (London, England)
Background The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030. Methods 16 in...
Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort st...
...Published in Lancet (London, England)
Background 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on ...
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcome...
...Published in Lancet (London, England)
Background Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cells—the target for rituximab—in the main disease tiss...
SOS Brazil: science under attack
Published in Lancet (London, England)
Neuropathology associated with SARS-CoV-2 infection
...Published in Lancet (London, England)
Neuropathology associated with SARS-CoV-2 infection
Published in Lancet (London, England)
South Africa responds to new SARS-CoV-2 variant
Published in Lancet (London, England)
CEPI criticised for lack of transparency
Published in Lancet (London, England)
